161 related articles for article (PubMed ID: 35797031)
1. Association Between Toxic Effects and Survival in Patients With Cancer and Autoimmune Disease Treated With Checkpoint Inhibitor Immunotherapy.
Han CY; Fitzgerald C; Lee M; Valero C; Gönen M; Shoushtari A; Morris LGT
JAMA Oncol; 2022 Sep; 8(9):1352-1354. PubMed ID: 35797031
[TBL] [Abstract][Full Text] [Related]
2. Adverse events induced by immune checkpoint inhibitors.
Perdigoto AL; Kluger H; Herold KC
Curr Opin Immunol; 2021 Apr; 69():29-38. PubMed ID: 33640598
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options.
Khan SA; Pruitt SL; Xuan L; Gerber DE
JAMA Oncol; 2016 Nov; 2(11):1507-1508. PubMed ID: 27262099
[No Abstract] [Full Text] [Related]
4. Autoimmune Cardiotoxicity of Cancer Immunotherapy.
Cheng F; Loscalzo J
Trends Immunol; 2017 Feb; 38(2):77-78. PubMed ID: 27919707
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
Kumar P; Saini S; Prabhakar BS
Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
[TBL] [Abstract][Full Text] [Related]
6. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.
Berner F; Bomze D; Diem S; Ali OH; Fässler M; Ring S; Niederer R; Ackermann CJ; Baumgaertner P; Pikor N; Cruz CG; van de Veen W; Akdis M; Nikolaev S; Läubli H; Zippelius A; Hartmann F; Cheng HW; Hönger G; Recher M; Goldman J; Cozzio A; Früh M; Neefjes J; Driessen C; Ludewig B; Hegazy AN; Jochum W; Speiser DE; Flatz L
JAMA Oncol; 2019 Jul; 5(7):1043-1047. PubMed ID: 31021392
[TBL] [Abstract][Full Text] [Related]
7. Editorial overview: Cancer Immunotherapy: Are we there yet?
Ohashi PS; Sharpe A
Curr Opin Immunol; 2021 Apr; 69():iii-v. PubMed ID: 33985756
[No Abstract] [Full Text] [Related]
8. [Involvement of regulatory B lymphocytes in susceptibility to autoimmune side effects of cancer immunotherapy].
Soussan S; Sibéril S
Med Sci (Paris); 2023 Feb; 39(2):101-104. PubMed ID: 36799742
[No Abstract] [Full Text] [Related]
9. Cancer immunotherapy in patients with preexisting autoimmune disorders.
Donia M; Pedersen M; Svane IM
Semin Immunopathol; 2017 Apr; 39(3):333-337. PubMed ID: 27730287
[TBL] [Abstract][Full Text] [Related]
10. Identifying and addressing the toxicity of checkpoint inhibitors in lung cancer.
Brahmer JR
Clin Adv Hematol Oncol; 2016 Mar; 14(3):165-7. PubMed ID: 27058029
[No Abstract] [Full Text] [Related]
11. Kobner phenomena as a complication of immune therapy of neoplastic disease.
James B
Autoimmunity; 1991; 10(2):165. PubMed ID: 1782328
[No Abstract] [Full Text] [Related]
12. Is autoimmunity the Achilles' heel of cancer immunotherapy?
June CH; Warshauer JT; Bluestone JA
Nat Med; 2017 May; 23(5):540-547. PubMed ID: 28475571
[TBL] [Abstract][Full Text] [Related]
13. Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?
Kostine M; Cappelli LC; Calabrese C; Calabrese LH; Bingham CO; Richez C; Gottenberg JE; Lambotte O
Ann Rheum Dis; 2019 Jun; 78(6):860-862. PubMed ID: 30659050
[No Abstract] [Full Text] [Related]
14. The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors.
Marchand L; Disse E; Dalle S; Reffet S; Vouillarmet J; Fabien N; Thivolet C; Cugnet-Anceau C
Acta Diabetol; 2019 Dec; 56(12):1239-1245. PubMed ID: 31423559
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead.
Patil PD; Burotto M; Velcheti V
Expert Rev Mol Diagn; 2018 Mar; 18(3):297-305. PubMed ID: 29430978
[TBL] [Abstract][Full Text] [Related]
16. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer.
Kehl KL; Yang S; Awad MM; Palmer N; Kohane IS; Schrag D
Cancer Immunol Immunother; 2019 Jun; 68(6):917-926. PubMed ID: 30877325
[TBL] [Abstract][Full Text] [Related]
17. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury.
Zen Y; Yeh MM
Mod Pathol; 2018 Jun; 31(6):965-973. PubMed ID: 29403081
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies.
Ferrari SM; Fallahi P; Elia G; Ragusa F; Ruffilli I; Patrizio A; Galdiero MR; Baldini E; Ulisse S; Marone G; Antonelli A
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137683
[TBL] [Abstract][Full Text] [Related]
19. Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology.
Hoa S; Laaouad L; Roberts J; Ennis D; Ye C; Al Jumaily K; Pope J; Nevskaya T; Saltman A; Himmel M; Rottapel R; Ly C; Colmegna I; Fifi-Mah A; Maltez N; Tisseverasinghe A; Hudson M; Jamal S
Cancer Immunol Immunother; 2021 Aug; 70(8):2197-2207. PubMed ID: 33471137
[TBL] [Abstract][Full Text] [Related]
20. Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy.
Olsen TA; Zhuang TZ; Caulfield S; Martini DJ; Brown JT; Carthon BC; Kucuk O; Harris W; Bilen MA; Nazha B
Front Endocrinol (Lausanne); 2022; 13():779915. PubMed ID: 35392134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
